RAFAEL HOLDINGS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
RAFAEL HOLDINGS, INC. (RFL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$131.00 thousand for the 3-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-04-30 was -$131.00K.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-01-31 was $378.00K.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2022-10-31 was -$127.00K, a 160.19% decline year-over-year.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2022-07-31 was $80.00K.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$504.00K, a 110.59% decline from fiscal 2021.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2021 was $4.76M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2023-04-30 | -$131.00K 10-Q · filed 2023-06-13 | $247.00K derived: sum of 2 quarters · filed 2023-06-13 | $120.00K 10-Q · filed 2023-06-13 | $200.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $378.00K 10-Q · filed 2023-03-14 | $251.00K 10-Q · filed 2023-03-14 | $331.00K derived: sum of 3 quarters · filed 2023-03-14 | -$10.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | -$127.00K 10-Q · filed 2022-12-13 | -$47.00K derived: sum of 2 quarters · filed 2022-12-13 | -$388.00K derived: sum of 3 quarters · filed 2023-06-13 | -$842.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-07-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | -$261.00K derived: sum of 2 quarters · filed 2023-06-13 | -$715.00K derived: sum of 3 quarters · filed 2023-06-13 | -$504.00K 10-K · filed 2022-10-31 |
| 2022-04-30 | -$341.00K 10-Q · filed 2023-06-13 | -$795.00K derived: sum of 2 quarters · filed 2023-06-13 | -$584.00K 10-Q · filed 2023-06-13 | |
| 2022-01-31 | -$454.00K 10-Q · filed 2023-03-14 | -$243.00K 10-Q · filed 2023-03-14 | ||
| 2021-10-31 | $211.00K 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | $4.76M 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |